1. Immunogenicity after six months of BNT162b2 vaccination in frail or disabled nursing home residents: the COVID-A Study
- Author
-
Ríos, SS, Zamora, EBC, Céspedes, AA, Rizos, LR, Sánchez-Jurado, PM, Sánchez-Nievas, G, Romero, MM, Tabernero Sahuquillo, MT, Señalada, JJB, Romero, AM, Nogueras, IG, De Dios Estrella Cazalla, J, Andrés-Pretel, F, Lauschke, VM, Stebbing, J, Abizanda, P, National Institute for Health Research, and Imperial College Healthcare NHS Trust- BRC Funding
- Subjects
Male ,Geriatrics & Gerontology ,Frail Elderly ,frailty ,immunogenicity ,nursing homes ,Humans ,Disabled Persons ,Longitudinal Studies ,older adults ,BNT162 Vaccine ,11 Medical and Health Sciences ,Aged ,Aged, 80 and over ,Science & Technology ,BNT162b2 vaccine ,Disability ,SARS-CoV-2 ,COVID-19 ,Spain ,Geriatrics ,Antibody Formation ,Female ,antibody titers ,Life Sciences & Biomedicine ,Gerontology - Abstract
BACKGROUND: There is incomplete information regarding evolution of antibody titers against SARS-CoV-2 after a two-dose strategy vaccination with BNT162b2, in older adults in long-term care facilities (LTCFs) with frailty, disability or cognitive impairment. We aimed to determine IgG antibody titer loss in old adults in LTCFs. METHODS: Multicenter longitudinal cohort study including 127 residents (90 females, 37 males) with a mean age of 82.7 years (range 65-99) with different frailty and disability profiles in two LTCFs in Albacete, Spain. Residents received 2 doses of BNT162b2 as per label, and antibody levels were determined 1 and 6 months after the second dose. Age, sex, previous history of COVID-19, comorbidity (Charlson index), performance in activities of daily living (Barthel index), frailty (FRAIL instrument), and cognitive status were assessed. RESULTS: The mean antibody titers 1 and 6 months after the second vaccine dose were 32,145 AU/mL (SD 41,206) and 6,182 AU/mL (SD 13,316) respectively. Across all participants, the median antibody titer loss measured 77.6% (IQR 23.8%). Notably, the decline of titers in individuals with pre-vaccination COVID-19 infection was significantly lower than in those without history of SARS-CoV-2 infection (72.2% vs 85.3%; p
- Published
- 2021